Key Financial Performance Highlights (Q1 FY 2026-27)
Consolidated Financials:
- Revenue from Operations: ₹3,037.33 Lakhs (₹30.37 Crore), compared to Nil revenue in Q1 FY26
- Total Income: ₹3,170.11 Lakhs (₹31.70 Crore)
- Net Profit After Tax: ₹106.26 Lakhs (₹1.06 Crore), reversing a Net Loss of ₹(91.00) Lakhs in Q1 FY26
- Profit Before Tax: ₹106.26 Lakhs
- Finance Costs: ₹0.07 Lakhs, down 99.62% YoY from ₹17.50 Lakhs in Q1 FY26
- Earnings Per Share: Basic and Diluted EPS at ₹0.07 per share (Face Value Re. 1/-), up from negative ₹(0.06) per share in Q1 FY26
Standalone Performance:
- Revenue from Operations: ₹1,196.90 Lakhs, compared to ₹0.65 Lakhs in Q1 FY26
- Net Profit: ₹96.83 Lakhs, compared to a Net Loss of ₹216.45 Lakhs in Q1 FY26
Strategic Business Update
The company announced its strategic entry into India's Longevity, Biohacking, and Preventive Healthcare market with the following strategic vectors:
Market Opportunity:
- Global longevity market projected to grow from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035 (9.41% CAGR)
- India's preventive healthcare market reached USD 197 Billion in 2025
- Anti-aging supplements expected to expand from USD 168.6 Million in 2025 to USD 341.4 Million by 2033 (9.5% CAGR)
- Anti-aging services expected to reach USD 1.06 Billion by 2035
Business Model:
- Dual approach integrating science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools
- Focus on tracking and optimizing metabolic health, sleep, cognition, and biological aging
- High-margin, recurring revenue potential through high repeat-purchase consumer wellness categories
- Leverages existing clinical capabilities for rapid regulatory validation
Management Commentary
Parmeshvar Dhangare, Director, stated: "Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization."
Company Description
TAKE Limited is described as a global technology company delivering domain-intensive solutions and services for the life sciences and supply chain industries. The company focuses on building scalable digital platforms and data-driven solutions to improve efficiency, compliance, and decision-making. Through expanding investments in AI, analytics, and digital health technologies, the company positions itself to participate in healthcare innovation.